CanStem111P trial: A Phase III study of napabucasin plus nab-paclitaxel with gemcitabine

Mohamad Bassam Sonbol, Daniel H. Ahn, David Goldstein, Takuji Okusaka, Josep Tabernero, Teresa Macarulla, Michele Reni, Chung Pin Li, Bert O'Neil, Eric Van Cutsem, Tanios Bekaii-Saab

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Napabucasin (also known as BBI-608 or BBI608) is an investigational, oral agent hypothesized to inhibit multiple oncogenic pathways. In this article, we describe the design and rationale for the CanStem111P clinical trial, a multicenter, randomized, open-label, Phase III study designed to determine the efficacy and safety of combining napabucasin with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma (NCT02993731). Patients were randomized in a 1:1 fashion to receive weekly gemcitabine and nab-paclitaxel with or without napabucasin. The results of this study will help define the role of this novel agent in the management of advanced pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)1295-1302
Number of pages8
JournalFuture Oncology
Issue number12
StatePublished - Apr 2019


  • BBI-608
  • CanStem111P
  • cancer stem cells
  • napabucasin
  • pancreatic adenocarcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'CanStem111P trial: A Phase III study of napabucasin plus nab-paclitaxel with gemcitabine'. Together they form a unique fingerprint.

Cite this